SCHEMBL1344198

SCHEMBL1344198

N#Cc1ccc(NC(=O)c2ccccc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.72
PLG P00747 1/20 0.72
PLAU P00749 1/20 0.72
KLKB1 P03952 1/20 0.72
PRSS1 P07477 1/20 0.72
NPC1 O15118 4/20 0.68
RAB9A P51151 4/20 0.68
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
MLYCD O95822 1/20 0.65
PTPN1 P18031 2/20 0.65
POLB P06746 2/20 0.64
MAPT P10636 2/20 0.64
PGR P06401 1/20 0.64
NAMPT P43490 1/20 0.63
SIRT1 Q96EB6 1/20 0.62
KDM4E B2RXH2 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.61
TAS1R3 Q7RTX0 1/20 0.59
TAS1R1 Q7RTX1 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3190254 0.93 MEN1 (0.68) F2PLGPLAUKLKB1PRSS1
SCHEMBL6263516 0.91 MLYCD (0.76) F2PLGPLAUKLKB1PRSS1
SCHEMBL9337665 0.91 MLYCD (0.76) F2PLGPLAUKLKB1PRSS1
SCHEMBL20764458 0.88 MLYCD (0.68) F2PLGPLAUKLKB1PRSS1
SCHEMBL31311100 0.88 MLYCD (0.68) F2PLGPLAUKLKB1PRSS1
SCHEMBL12700258 0.85 MEN1 (0.69) F2PLGPLAUKLKB1PRSS1
SCHEMBL9587298 0.85 MEN1 (0.65) F2PLGPLAUKLKB1PRSS1
SCHEMBL126415 0.84 PTPN1 (0.87) NPC1RAB9AMEN1KMT2APTPN1
SCHEMBL5561129 0.84 PLAU (1.00) F2PLGPLAUKLKB1PRSS1
SCHEMBL18177305 0.84 PGR (0.65) F2PLGPLAUKLKB1PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4483376-A1 MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME García Sada, Fernando (MX) 2025-01-01 EP claimed
CN-118922890-A Measurement, diagnosis, treatment and management of metabolic syndrome 费尔南多·加西亚·萨达 2024-11-08 CN claimed
WO-2023161832-A1 MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME GARCIA SADA FERNANDO (MX) 2023-08-31 WO claimed
US-20230266340-A1 Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome SILTI AG (CH) 2023-08-24 US claimed
EP-1575575-A2 SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2005-09-21 EP claimed
US-20040138301-A1 Chemical uncouplers for the treatment of obesity HIGH POINT PHARMACEUTICALS, LLC 2004-07-15 US claimed
WO-2004041256-A2 SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2004-05-21 WO claimed
EP-0775110-A1 ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS WARNER-LAMBERT COMPANY (US) 1997-05-28 EP claimed
WO-1996004242-A1 ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS WARNER-LAMBERT COMPANY (US) 1996-02-15 WO claimed
US-12269814-B2 Process for preparing a compound useful to treat mycoses PULMOCIDE LIMITED (GB) 2025-04-08 US disclosed
EP-4483376-A1 MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME García Sada, Fernando (MX) 2025-01-01 EP disclosed
CN-116199599-B Method for preparing aryl nitrile compound 江苏师范大学 2024-11-15 CN disclosed
CN-118922890-A Measurement, diagnosis, treatment and management of metabolic syndrome 费尔南多·加西亚·萨达 2024-11-08 CN disclosed
CN-118048636-B Electrocatalytic synthesis method for N-aryl amide 平顶山学院 2024-09-13 CN disclosed
WO-2004041256-A2 SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2004-05-21 WO disclosed
WO-2004009563-A1 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR INOTEK PHARMACEUTICALS CORPORATION (US) 2004-01-29 WO disclosed
US-20040019208-A1 5-Aryltetrazole Compounds, compositions thereof, and uses therefor INOTEK PHARMACEUTICALS CORPORATION 2004-01-29 US disclosed
CN-1155278-A Arylthio compounds as antibacteral and antiviral agents WARNER LAMBERT CO (US) 1997-07-23 CN disclosed
EP-0495626-A1 Process for the preparation of tetrazole derivatives ZENECA LIMITED (GB) 1992-07-22 EP disclosed
US-4499167-A Photoconductive compositions comprising an organic photoconductor and an amide compound and electro-photographic light-sensitive materials using the compositions FUJI PHOTO FILM CO., LTD. (JP) 1985-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138301-A1 Chemical uncouplers for the treatment of obesity PC, CPT2, IDH2 F2 3551/4885PLG 1371/4885PLAU 2448/4885
US-20040019208-A1 5-Aryltetrazole Compounds, compositions thereof, and uses therefor CASP5, NLRP3, LITAF F2 1420/4885PLG 129/4885PLAU 132/4885
US-12269814-B2 Process for preparing a compound useful to treat mycoses C1R, CBR1, CBR3 F2 2967/4885PLG 4638/4885PLAU 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.